Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel with Radiation and Hormone Therapy in High-Risk Localized Prostate Cancer
NCT03432780Phase 2Unknown
- Sponsor
- SOGUG
- Start
- Dec 2008
- Primary completion
- Nov 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of docetaxel in prostate cancer (PCa) (2 arms), sponsored by SOGUG. Primary endpoint: Percentage of patients free of biochemical recurrence at 5 years. Status: unknown.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03432780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03432780.